Drug class in one race
GLP-1/GIP receptor (dual) drugs for Type 2 Diabetes
3 tracked GLP-1/GIP receptor (dual) drugs in the Type 2 Diabetes race. The class explanation lives on the GLP-1/GIP receptor (dual) page; the full indication pipeline across every mechanism is on the Type 2 Diabetes page.
1 approved / phase 42 Phase 3
Head-to-head evidence: ribupatide vs VK2735 · tirzepatide vs VK2735 · ribupatide vs tirzepatide